Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells

Molecular and Cellular Endocrinology

Volumn 264, Issue 1-2, 2007, Pages 74-81

  Hoffmann, Sebastian ^a   Rockenstein, Andreas ^a   Ramaswamy, Anette ^a   Celik, Ilhan ^a   Wunderlich, Anette ^a   Lingelbach, Susanne ^a   Hofbauer, Lorenz C ^a   Zielke, Andreas ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Angiogenesis; Retinoic acid; Thyroid cancer; Tumor proliferation; VEGF

Indexed keywords

PROTEIN; RADIOACTIVE IODINE; RETINOIC ACID; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER STAGING; CELL COUNT; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MICROVASCULATURE; MORPHOMETRICS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; THYROID CANCER; TUMOR GROWTH; TUMOR VOLUME; XENOTRANSPLANTATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; THYROID NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TRETINOIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846206474     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2006.10.009     Document Type: Article

References (53)

1. Altucci L., and Gronemeyer H. The promise of retinoids to fight against cancer. Nat. Rev. Cancer 1 (2001) 181-193
2. Ambiosi-Impiombato F.S., Parks L.A.M., and Coon H.G. Culture of hormone dependent epithelial cells from rat thyroids. Proc. Natl. Acad. Sci. U.S.A. 77 (1980) 3455-3459
3. Barth P.J., Weingärtner K., Köhler H.H., and Bittinger A. Assessment of the vascularization in prostatic carcinoma: a morphometric investigation. Hum. Pathol. 27 (1996) 1306-1310
4. Bauer A.J., Terrell R., Doniparthi N.K., Patel A., Tuttle R.M., Saji M., Ringel M.D., and Francis G.L. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid 12 (2002) 953-961
5. Bohnsack B.L., Lai L., Dolle P., and Hirschi K.K. Signaling hierarchy downstream of retinoic acid that independently regulates vascular remodeling and endothelial cell proliferation. Genes Dev. 18 (2004) 1345-1358
6. Boyle B.J., Harris V.K., Liaudet-Coopman E.D., Riegel A.T., and Wellstein A. Differential regulation of a fibroblast growth factor-binding protein by receptor-selective analogs of retinoic acid. Biochem. Pharmacol. 60 (2000) 1677-1684
7. Cho D.H., Choi Y.J., Jo S.A., Nam J.H., Jung S.C., and Jo I. Retinoic acid decreases nitric oxide production in endothelial cells: a role of phosphorylation of endothelial nitric oxide synthase at Ser(1179). Biochem. Biophys. Res. Commun. 326 (2005) 703-710
8. Chomienne C., Fenaux P., and Degos L. Retinoid differentiation therapy in promyelocytic leukemia. FASEB J. 10 (1996) 1025-1030
9. Coelho S.M., Corbo R., Buescu A., Carvalho D.P., and Vaisman M. Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma. J. Endocrinol. Invest. 27 (2004) 334-338
10. Connolly D.T., Knight M.B., Harakas N.K., Wittwer A.J., and Feder J. Determination of the number of endothelial cells in culture using an acid phosphatase assay. Ann. Biochem. 152 (1986) 136-140
11. Diaz B.V., Lenoir M.C., Ladoux A., Frelin C., Demarchez M., and Michel S. Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids. J. Biol. Chem. 275 (2000) 642-650
12. Elisei R., Vivaldi A., Agate L., Ciampi R., Molinaro E., Piampiani P., Romei C., Faviana P., Basolo F., Miccoli P., Capodanno A., Collecci P., Pacini F., and Pincherra A. All-trans retinoic acid treatment inhibits the growth of RAR-β mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes. J. Clin. Endocrinol. Metab. 90 (2004) 2403-2411
13. Folkmann J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 82 (1990) 4-6
14. Goretzki P.E., Simon D., Dotzenrath C., Schulte K.M., and Roher H.D. Growth regulation of thyroid and thyroid tumors in humans. World J. Surg. 24 (2000) 913-922
15. Gruning T., Tiepolt C., Zophel K., Bredow J., Kropp J., and Franke W.G. Retinoic acid for redifferentiation of thyroid cancer-does it hold its promise?. Eur. J. Endocrinol. 148 (2003) 395-402
16. Grunwald F., Menzel C., Bender H., Palmedo H., Otte R., Fimmers R., Risse J., and Biersack H.J. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J. Nucl. Med. 39 (1998) 1903-1906
17. Hanahan D., and Folkmann J. Patterns and emerging mechanisms of the angiogenetic switch during tumorigenesis. Cell 86 (1996) 353-364
18. Haugen B.R., Larson L.L., Pugazhenthi U., Hays W.R., Klopper J.P., Kramer C.A., and Sharma V. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J. Clin. Endocrinol. Metab. 89 (2004) 272-280
19. Hoang-Vu C., Bull K., Schwarz I., Krause G., Schmutzler C., Aust G., Koehrle J., and Dralle H. Regulation of CD97 protein in thyroid carcinoma. J. Clin. Endocrinol. Metab. 84 (1999) 1104-1109
20. Hoffmann S., Hofbauer L.C., Scharrenbach V., Wunderlich A., Hassan I., Lingelbach S., and Zielke A. TSH-induced production of VEGF in thyroid cancer cells in vitro: evaluation of TSH-signal transduction and of angiogenesis-stimulating growth factors. J. Clin. Endocrinol. Metab. 89 (2004) 6139-6145
21. Hoffmann S., Wunderlich A., Celik I., Maschuw K., Hassan I., Lingelbach S., and Zielke A. Paneling human thyroid cancer cell lines for candidate proteins for targeted anti-angiogenic therapy. J. Cell. Biochem. 10 (2006) (Epub ahead of print)
22. Kerbel R., and Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2 (2002) 727-739
23. Kooistra T., Lansink M., Arts J., Sitter T., and Toet K. Involvement of retinoic acid receptor alpha in the stimulation of tissue-type plasminogen-activator gene expression in human endothelial cells. Eur. J. Biochem. 232 (1995) 425-432
24. Kurebayashi J., Tanaka K., Otsuki T., Moriya T., Kunisue H., Uno M., and Sonoo H. All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J. Clin. Endocrinol. Metab. 85 (2000) 2889-2896
25. Lai L., Bohnsack B.L., Niederreither K., and Hirschi K.K. Retinoic acid regulates endothelial cell proliferation during vasculogenesis. Development 130 (2003) 6465-6474
26. Lennard C.M., Patel A., Wilson J., Reinhardt B., Tuman C., Fenton C., Blair E., Francis G.L., and Tuttle R.M. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 129 (2001) 552-558
27. Marchetti M., Vignoli A., Bani M.R., Balducci D., Barbui T., and Falanga A. All-trans retinoic acid modulates microvascular endothelial cell hemostatic properties. Haematologica 88 (2003) 895-905
28. Menth M., Schmutzler C., Mentrup B., Hoang-Vu C., Takahashi K., Honjoh T., and Kohrle J. Selenoprotein expression in Hurthle cell carcinomas and in the human Hurthle cell carcinoma line XTC.UC1. Thyroid 15 (2005) 405-416
29. Minagawa N., Nakayama Y., Inoue Y., Onitsuka K., Katsuki T., Tsurudome Y., Shibao K., Hirata K., Sako T., Nagata N., Ohie S., Kohno K., and Itoh H. 4-[3,5-Bis(trimethylsilyl) benzamido] benzoic acid inhibits angiogenesis in colon cancer through reduced expression of vascular endothelial growth factor. Oncol. Res. 14 (2004) 407-414
30. Oikawa T., Okayasu I., Ashino H., Morita I., Murota S., and Shudo K. Three novel synthetic retinoids, Re 80, Am 580 and Am 80, all exhibit anti-angiogenic activity in vivo. Eur. J. Pharmacol. 249 (1993) 113-116
31. Pal S., Iruela-arispe M.L., Harvey V.S., Zeng H., Nagy J.A., Dvorak H.F., and Mukopadhyay D. Retinoic acid selectively inhibits the vascular permeabilizing effect of VPF/VEGF, an early step in the angiogenic cascade. Microvasc. Res. 60 (2000) 112-120
32. Pasieka J.L. Anaplastic thyroid cancer. Curr. Opin. Oncol. 15 (2003) 78-83
33. Schmutzler C., Winzer R., Meissner-Weigl J., and Kohrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem. Biophys. Res. Commun. 240 (1997) 832-838
34. Schmutzler C., Brtko J., Winzer R., Jakobs T.C., Meissner-Weigl J., Simon D., Goretzki P., and Koehrle J. Functional retinoid and thyroid hormone receptors in human thyroid-carcinoma cell lines and tissues. Int. J. Cancer 76 (1998) 368-376
35. Schmutzler C., and Kohrle J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 10 (2000) 393-406
36. Schmutzler C. Regulation of the sodium/iodide symporter by retinoids-a review. Exp. Clin. Endocrinol. Diab. 109 (2001) 41-44
37. Schmutzler C., Hoang-Vu C., Ruger B., and Köhrle J. Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses. Eur. J. Endocrinol. 150 (2004) 547-560
38. Scholz I.V., Cengic N., Baker C.H., Harrington K.J., Maletz K., Bergert E.R., Vile R., Gocke B., Morris J.C., and Spitzweg C. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Ther. 12 (2005) 272-280
39. Schreck R., Schnieders F., Schmutzler C., and Köhrle J. Retinoids stimulate type I iodothyronine 50-deiodinase activity in human follicular thyroid carcinoma cell lines. J. Clin. Endocrinol. Metab. 79 (1994) 791-798
40. Sharma V., Hays W.R., Wood W.M., Pugazhenthi U., St. Germain D.L., Bianco A.C., Krezel W., Chambon P., and Haugen B.R. Effects of rexinoids on thyrotrope function and the hypothalamic-pituitary-thyroid axis. Endocrinology 147 (2006) 1438-1451
41. Sherman S.I. Thyroid carcinoma. Lancet 361 (2003) 501-511
42. Simon D., Köhrle J., Reiners C., Boerner A.R., Schmutzler C., Mainz K., Goretzki P., and Roher H.D. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J. Surg. 22 (1998) 569-574
43. Simon D., Korber C., Krausch M., Segering J., Groth P., Gorges R., Grunwald F., Gartner H.W., Schmutzler C., Koehrle J., Roher H.D., and Reiners C. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur. J. Nucl. Med. Mol. Imaging 29 (2002) 775-782
44. Soh E.Y., Duh Q.Y., Sobhi S.A., Young D.M., Epstein H.D., Wong M.G., Garcia Y.K., Min Y.D., Grossman R.F., Siperstein A.E., and Clark O.H. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J. Clin. Endocrinol. Metab. 82 (1997) 3741-3747
45. Spitzweg C., O'Connor M.K., Bergert E.R., Tindall D.J., Young C.Y., and Morris J.C. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res. 60 (2000) 6526-6530
46. Spitzweg C., Scholz I.V., Bergert E.R., Tindall D.J., Young C.Y., Goke B., and Morris J.C. Retinoic acid-induced stimulation of sodium iodide symporter expression and cytotoxicity of radioiodine in prostate cancer cells. Endocrinology 144 (2003) 3423-3432
47. Suzuki Y., Komi Y., Ashino H., Yamashita J., Inoue J., Yoshiki A., Eichmann A., Amanuma H., and Kojima S. Retinoic acid controls blood vessel formation by modulating endothelial and mural cell interaction via suppression of Tie2 signaling in vascular progenitor cells. Blood 104 (2004) 166-169
48. Tokuda H., Hatakeyama D., Akamatsu S., Tanabe K., Yoshida M., Shibata T., and Kozawa O. Involvement of MAP kinases in TGF-beta-stimulated vascular endothelial growth factor synthesis in osteoblasts. Arch. Biochem. Biophys. 415 (2003) 117-125
49. Van Herle A.J., Agatep M.L., Padua D.N., Totanes T.L., Canlapan D.V., van Herle H.M.L., and Juillard G.J.F. Effects of 13-cis retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA RO 82 W-1) in vitro. J. Clin. Endocrinol. Metab. 71 (1990) 755-763
50. Viglietto G., Maglione D., Rambaldi M., Cerutti J., Romano A., Trapasso F., Fedele M., Ippolito P., Chiappetta G., and Botti G. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11 (1995) 1569-1579
51. Younes M.N., Yigitbasi O.G., Park Y.W., Kim S.J., Jasser S.A., Hawthorne V.S., Yazici Y.D., Mandal M., Bekele B.N., Bucana C.D., Fidler I.J., and Myers J.N. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation. Cancer Res. 65 (2005) 4716-4727
52. Zielke A., Tezelman S., Jossart G.H., Wong M., Siperstein A.E., Duh Q.Y., and Clark O.H. Establishment of a highly differentiated thyroid cancer cell line of Huerthle cell origin. Thyroid 8 (1998) 475-483
53. Zielke A., Middeke M., Hoffmann S., Colombo-Benkmann M., Barth P., Hassan I., Wunderlich A., Hofbauer L.C., and Duh Q.J. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery 132 (2002) 1056-1063